Recurrent Fallopian Tube Carcinoma Clinical Trials
2 recruiting trials for Recurrent Fallopian Tube Carcinoma. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Recurrent Fallopian Tube Carcinoma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
The only sponsor on record for these trials is Roswell Park Cancer Institute (2 trials).
The most frequently studied intervention is Questionnaire Administration (other, 2 trials), followed by Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab.
Track Recurrent Fallopian Tube Carcinoma trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With...
This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that...
An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage...
This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Recurrent Fallopian Tube Carcinoma, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Recurrent Fallopian Tube Carcinoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Recurrent Fallopian Tube Carcinoma, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.